Login to Your Account

Deals Roundup

Two Aussie Biotechs Merging to Focus on Phase III HIV Dru

By Catherine Hollingsworth

Tuesday, December 23, 2008
Australian biotech firms Progen Pharmaceuticals Ltd. and Avexa Ltd. have agreed to merge, creating a new company with a well-funded oncology and HIV pipeline. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription